Clinical Trials Logo

Clinical Trial Summary

This study will assess whether it is feasible to remove small breast cancers completely using the Breast Lesion Excision System under Ultrasound guidance.


Clinical Trial Description

Rationale: In the Netherlands, ≥7000 women are operated for small breast cancers yearly. In this study, we will evaluate under which conditions it is possible to excise small breast cancers using the Breast Lesion Excision System (BLES) under ultrasound (US) guidance. When successful, this will allow ambulatory treatment of women with small breast cancers, improving the cosmetic outcome and quality of life.

Objective: Our study aim is to assess whether it is feasible to remove small breast cancers completely using the BLES system under US guidance.

Study design: This is a multi-centre, translational clinical phase II study in 125 women with cancers ≤1.5 cm based upon US measurements, and without mammographic evidence of more extensive disease (e.g. microcalcifications).

Study population: Women with cancers ≤1.5 cm based upon US measurements, if there is no mammographic evidence of more extensive disease (e.g. microcalcifications or extensive architectural distortion), and the tumor lies ≥6 mm away from the dermis, nipple or pectoral muscle, are eligible for this study.

Intervention: In 125 women with cancers ≤1.5 cm based upon US measurements, and without mammographic evidence of more extensive disease (e.g. microcalcifications), we will conduct additional preoperative breast MRI to ascertain lesion size, after informed consent has been obtained. If the lesion is confirmed ≤1.5 cm on MRI and lying ≥6 mm away from the dermis, nipple and pectoral muscle, the patient is eligible. Moreover, patients will be asked to fill out the questionnaire, detailing their risk profile and comorbidity index.

Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance, through a small skin incision (<1 cm). Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure. Margin assessment will be performed separately for the BLES excision and the surgical specimen of the surrounding tissue.

Main study parameters/endpoints: Main endpoint of the study is the frequency of successful complete tumor excision by the BLES system, where successful is defined as 'having tumor free margins, and no residual (in situ) cancer in the surgical specimen'.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Our approach allows to test the feasibility of this highly innovating approach to remove breast cancer, with minimal negative effects or possible complications.

While there is no direct benefit nor detrimental effect from this study to the patients participating, the study has large implications for many women, as breast cancer remains the most common cancer in women, and due to screening, most cancers are small. Further reduction of the impact of local treatment is still desired as the psychosocial and somatic effects of breast deformation can be substantial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02975128
Study type Interventional
Source Radboud University
Contact
Status Terminated
Phase N/A
Start date February 19, 2018
Completion date July 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT02944604 - The Efficacy and Safety of PEG-rhG-CSF(Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy Phase 4
Completed NCT03012152 - A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction N/A
Terminated NCT04168957 - An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 Phase 1
Recruiting NCT02967146 - Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer Phase 3
Completed NCT02958332 - Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer N/A
Completed NCT03030677 - Establishing Technique for PECS2 Catheter Insertion N/A
Completed NCT03165955 - A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients Phase 1
Completed NCT03066947 - SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Phase 1/Phase 2
Recruiting NCT02992574 - Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer N/A
Completed NCT02964234 - Empowering Latinas to Obtain Breast Cancer Screenings N/A
Completed NCT02996240 - Breast, Omega 3 Free Fatty Acid, Ph 0 N/A
Completed NCT03010371 - Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors. N/A
Completed NCT02209857 - The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy N/A
Completed NCT03014076 - Immunotherapy Vaccine and Herceptin in Breast Cancer Phase 1
Active, not recruiting NCT03121248 - Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years N/A
Active, not recruiting NCT02997384 - Feasibility of Breast Cancer Risk Evaluation in Women From the General Population N/A
Completed NCT03012893 - Identification of C7; Evaluations of 2 Sonographic Methods Using a Transverse and a Sagittal Scan. N/A
Completed NCT03023007 - Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on Chronic Pain of a Mastectomy N/A
Completed NCT04993040 - A PK Study of Oraxol in Breast Cancer Patients Phase 1
Completed NCT02992067 - CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer